Hologic Azione

Hologic Conversione FCF

Delisted·7 apr 2026

Il Tasso di Conversione FCF (FCF/EBITDA) di Hologic (HOLX) al 17 ago 2026 è 162,65 %. L'anno precedente, Tasso di Conversione FCF (FCF/EBITDA) era 145,03 % — una variazione del 12,15% (superiore).

Conversione FCF

162,65 %

YoY

12,15%

Ultimo aggiornamento:

Tasso di Conversione FCF (FCF/EBITDA) di Hologic ammonta a 2026 162,65 % . Tasso di Conversione FCF (FCF/EBITDA) di Hologic ammontava a 2025 145,03 % . Diminuisce del 12,15% superiore rispetto all'anno precedente.
Access this data via the Eulerpool API

Hologic Analisi delle Azioni

Cosa fa Hologic? Hologic Inc. is a company from the United States that has established itself in the medical technology market. The company was founded in 1985 by Jay A. Stein, who set the goal of developing products and services that contribute to improving people's lives. Hologic specializes in artificial intelligence (AI) based diagnostic and therapeutic technology that increases the safety, effectiveness, and accuracy of medical procedures. The company initially focused on products in the field of mammography, but has since expanded to various sectors including imaging, gynecology, skeletal, and surgery. Hologic offers its customers products such as tomosynthesis systems, robot-assisted surgery systems, image analysis software, and a variety of reagents, kits, and tests. The company's business model is focused on innovative technology and science, aiming to optimize medical interventions and thus reduce and improve healthcare costs. Hologic is dedicated to research and development and has already filed dozens of patents. In the field of breast cancer diagnostics, Hologic has developed various mammography systems that have broken the standard of mammography. Through the use of tomosynthesis, a 3D-based diagnostic, it is possible to detect tumors and malignant changes earlier. This procedure has been widely used by many doctors around the world and has proven to be a reliable method for early detection of breast cancer. In gynecology, Hologic specializes in the development of diagnostic tests for infectious agents and hormones. The tests, such as the Aptima HPV test, are fast, sensitive, and reliable. They help to detect infectious agents earlier and initiate appropriate therapy. Hologic Taurus, a robot-assisted surgery system, has been developed to enable minimally invasive interventions that can be used to treat uterine fibroids. This method allows for a drastic reduction in hospital stay duration and recovery time. In the field of skeletal, Hologic offers various systems that are helpful in the diagnosis and treatment of osteoporosis. The widely used DXA system (Dual-Energy X-Ray Absorptiometer) is still one of the most accurate devices for measuring bone density. Additionally, Hologic is an company that not only focuses on medical technology but also pursues the larger goal of improving people's lives. An example of this is their partnership with the organization Pink Ribbon, which serves as a global ambassador for breast cancer early detection. Hologic has developed a special mammography system called Pink Affirm. For every system sold, Hologic donates a certain amount to Pink Ribbon. Overall, Hologic Inc. has become an important player in the field of medical technology and diagnostics. Through its innovative technologies and products, the company contributes to improving the health and lives of people worldwide. Hologic è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su Hologic azioni

Tasso di Conversione FCF (FCF/EBITDA) di Hologic è 162,65 % nel 2026.

Il Tasso di Conversione FCF (FCF/EBITDA) di Hologic è passato da 145,03 % a 162,65 %, con una variazione del 12,15 %. Il valore è superiore rispetto all'anno precedente.

Su Eulerpool è possibile consultare lo sviluppo storico completo del Hologic di Tasso di Conversione FCF (FCF/EBITDA) dal 2006, con valori annuali, grafici e analisi dettagliate.

La conversione FCF misura l'efficacia con cui l'EBITDA si converte in flusso di cassa libero. Una conversione più elevata indica un'efficiente allocazione di capitale e bassi costi di manutenzione.

Un 'buono' varia a seconda del settore e della fase di sviluppo dell'azienda. Su Eulerpool puoi confrontare Hologic di Tasso di Conversione FCF (FCF/EBITDA) con i competitor del settore e la media industriale per valutare se è attraente.

Per valutare di Tasso di Conversione FCF (FCF/EBITDA), è essenziale confrontarlo con i competitor nello stesso settore e industria. Su Eulerpool puoi trovare confronti diretti con l'industria per Tasso di Conversione FCF (FCF/EBITDA).

Access this data via the Eulerpool API

Flussi di cassa — Hologic

Tutte le Metriche Finanziarie — Hologic